http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2603960-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_49ed215918377574cf355bfdf0937f28 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2015-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2979d6ef19b18ac6c5f5de8b1a4e224f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be86965998fbffe3122384f1cf67cb03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a5de4ca383a4d2fbc558c92769b8119 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_167b22fed3314721b82a05b74d127144 |
| publicationDate | 2016-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2603960-C1 |
| titleOfInvention | Dichloroacetate of n1,n2-disubstituted n4-[4-(1-methyl-1h-indole-3-yl)-pyrimidine-2-yl]-5-methoxybenzene-1,2,4-triamine as egfr modulator for treating cancer |
| abstract | FIELD: chemistry, medicine. n SUBSTANCE: invention relates to novel salt - dichloroacetate N-{2-[(2-dimethylaminoethyl)methyl-amino]-5-[4-(1-methyl-1H-indole-3-yl)pyrimidin-2-ylamino]-4-methoxyphenyl}acrylamide, which has properties of EGFR inhibitor and can be used for treating cancer types, mediated by EGFR and its mutants selected from L858R, 1790M and Exon19. Compound may be used for treating ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, prostate cancer, melanoma, leukemia, non-Hodgkin lymphoma, stomach cancer, lung cancer and hepatocellular cancer, gastrointestinal stromal tumors (GIST), thyroid cancer, bile duct cancer, endometrial cancer, renal cancer, anaplastic large cell lymphoma, acute myeloid leukemia, multiple myeloma, melanoma and mesothelioma. Preferably compound can be used for preventing and/or treating mutations of epidermal growth factor receptor EGFRm of non-small cell lung cancer (NSCLC), which also have resistent mutation T790M. N-{2-[(2-dimethylaminoethyl)methyl-amino]-5-[4-(1-methyl-1H-indole-3-yl)pyrimidin-2-ylamino]-4-methoxyphenyl}acrylamide dichloroacetate corresponds to general formula 1 n . n EFFECT: prevention and/or treatment of mutations of epidermal growth factor receptor EGFRm in non-small cell lung cancer (NSCLC). n 12 cl, 2 tbl, 6 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102590637-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3603638-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2780016-C1 |
| priorityDate | 2015-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.